// App-Quantinova.ai

: Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

Researchers

Presenter

  • Stephan Stilgenbauer

Principal Investigators

  • Franck Morschhauser

  • Clemens-Martin Wendtner

  • Guillaume Cartron

  • Michael Hallek

  • Barbara Eichhorst

  • Mark F. Kozloff

  • Thomas Giever

  • Gerard Lozanski

  • Yanwen Jiang

  • Huang Huang

  • Daniela Soriano Pignataro

  • William Schary

  • Kathryn Humphrey

  • Mehrdad Mobasher

  • Gilles Salles

Medical Centers

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Hematologie, Centre Hospitalier Universitaire, Universite de Lille, EA GRIIOT, Lille, France

  • Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany

  • Department of Gastroenterology, CHU de Montpellier, Montpellier, France

  • Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • The University of Chicago Medical Center, Chicago, IL

  • Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.

  • Department of Pathology, The Ohio State University, Columbus, OH

  • Genentech, Inc., South San Francisico, CA

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • AbbVie, Inc., North Chicago, IL

  • Genentech, Inc., South San Francisico, CA

  • Department of Nuclear Medicine, Hospices Civils de Lyon, CHU Lyon Sud, University Claude Bernard Lyon 1, Pierre Benite, France

Locations

  • Germany

  • France

  • United States

  • Canada

  • United Kingdom

Companies

  • Feng Chi Biotech Cor

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved